Scholarlink

Background <p>Immunoglobulin A nephropathy (IgAN), the most common glomerular disease, is characterized by immune complex deposition and abnormal complement system activation. Telitacicept targets B cells through multiple mechanisms, potentially offering therapeutic benefits in IgAN. This retrospective study aimed to evaluate the efficacy and safety of telitacicept.</p> Methods <p>Eleven patients with IgAN treated with telitacicept (160&#xa0;mg, weekly) between August 2022 and December 2024 were included. The minimum follow-up period was 24 weeks, and the primary endpoint was renal remission rate at the final visit.</p> Results <p>Among the 11 patients, 6 (54.5%) achieved partial remission, including 3 (27.3%) with complete response. Following telitacicept treatment, 24-h proteinuria decreased from a baseline of 1.77&#xa0;g/day (interquartile range [IQR]: 1.31–5.19&#xa0;g/day) to 1.04&#xa0;g/day (IQR: 0.27–1.41&#xa0;g/day) at the last follow-up (<i>P</i> &lt; 0.05), demonstrating a significant reduction in proteinuria. Urinary red blood cell counts decreased from 52.81 ± 110.95 to 9.62 ± 11.44 per high-power field. The main adverse reaction was an upper respiratory tract infection, with no serious events reported.</p> Conclusion <p>This study provided preliminary evidence that telitacicept may reduce proteinuria in patients with IgAN, with no serious safety concerns observed during this study. These preliminary real-world findings support the potential role of telitacicept in IgAN management and warrant confirmation in prospective multicenter studies.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of telitacicept in the treatment of immunoglobulin a nephropathy: a real-world, single-center, retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • Lunju Luo,
  • Yiyao Deng,
  • Shuang Chen,
  • Yuqi Yang,
  • Lu Liu,
  • Rui Zhang,
  • Zhengsheng Li,
  • Lu Yang,
  • Yan Zha,
  • Jing Yuan

摘要

Background

Immunoglobulin A nephropathy (IgAN), the most common glomerular disease, is characterized by immune complex deposition and abnormal complement system activation. Telitacicept targets B cells through multiple mechanisms, potentially offering therapeutic benefits in IgAN. This retrospective study aimed to evaluate the efficacy and safety of telitacicept.

Methods

Eleven patients with IgAN treated with telitacicept (160 mg, weekly) between August 2022 and December 2024 were included. The minimum follow-up period was 24 weeks, and the primary endpoint was renal remission rate at the final visit.

Results

Among the 11 patients, 6 (54.5%) achieved partial remission, including 3 (27.3%) with complete response. Following telitacicept treatment, 24-h proteinuria decreased from a baseline of 1.77 g/day (interquartile range [IQR]: 1.31–5.19 g/day) to 1.04 g/day (IQR: 0.27–1.41 g/day) at the last follow-up (P < 0.05), demonstrating a significant reduction in proteinuria. Urinary red blood cell counts decreased from 52.81 ± 110.95 to 9.62 ± 11.44 per high-power field. The main adverse reaction was an upper respiratory tract infection, with no serious events reported.

Conclusion

This study provided preliminary evidence that telitacicept may reduce proteinuria in patients with IgAN, with no serious safety concerns observed during this study. These preliminary real-world findings support the potential role of telitacicept in IgAN management and warrant confirmation in prospective multicenter studies.

Clinical trial number

Not applicable.